Open Label, Randomized Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Two Doses of an Octreotide Implant in Patients With Carcinoid Syndrome.

Trial Profile

Open Label, Randomized Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Two Doses of an Octreotide Implant in Patients With Carcinoid Syndrome.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 19 Sep 2013

At a glance

  • Drugs Octreotide (Primary)
  • Indications Malignant carcinoid syndrome
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Aug 2012 Actual end date Dec 2011 added as reported by ClinicalTrials.gov.
    • 16 Aug 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 22 Jul 2011 Planned End Date changed from 1 Feb 2011 to 1 Nov 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top